相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Heart rate reduction with ivabradine improves left ventricular function and reverses multiple pathological maladaptations in dogs with chronic heart failure
Hani N. Sabbah et al.
ESC HEART FAILURE (2014)
Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction
Jan-Christian Reil et al.
EUROPEAN HEART JOURNAL (2013)
Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients
Jan-Christian Reil et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?
Damien Cullington et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure
Davide Castagno et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
Jean-Claude Tardif et al.
EUROPEAN HEART JOURNAL (2011)
Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac Fibrosis
David Busseuil et al.
CARDIOLOGY (2010)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Karl Swedberg et al.
LANCET (2010)
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
Michael Boehm et al.
LANCET (2010)
Meta-analysis: beta-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
Finlay A. McAlister et al.
ANNALS OF INTERNAL MEDICINE (2009)
Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart
Claudio Ceconi et al.
CARDIOVASCULAR RESEARCH (2009)
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
Kim Fox et al.
EUROPEAN HEART JOURNAL (2009)
Sympathetic Nervous System Activation in Human Heart Failure Clinical Implications of an Updated Model
John S. Floras
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The Sympathetic Nervous System in Heart Failure Physiology, Pathophysiology, and Clinical Implications
Filippos Triposkiadis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers
Genevieve Flannery et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice
Florian Custodis et al.
CIRCULATION (2008)
Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379 843 men and women aged 40-45 years
Aage Tverdal et al.
EUROPEAN HEART JOURNAL (2008)
Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure
Gaetano M. De Ferrari et al.
EUROPEAN JOURNAL OF HEART FAILURE (2008)
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
Kim Fox et al.
LANCET (2008)
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
Kim Fox et al.
LANCET (2008)
Mechanisms of sympathetic activation in heart failure
A. M. D. Watson et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
The effect of altering heart rate on ventricular function in patients with heart failure treated with β-blockers
Simon D. R. Thackray et al.
AMERICAN HEART JOURNAL (2006)
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
M Metra et al.
EUROPEAN HEART JOURNAL (2005)
Assessing cardiorespiratory fitness without performing exercise testing
R Jurca et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2005)
Physiology and pharmacology of the cardiac pacemaker (funny) current
M Baruscotti et al.
PHARMACOLOGY & THERAPEUTICS (2005)
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?: Experiences from the Metoprolol Controlled Release Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)
L Gullestad et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure
P Mulder et al.
CIRCULATION (2004)
Effects of carvedilol on left ventricular remodeling after acute myocardial infarction -: The CAPRICORN echo substudy
RN Doughty et al.
CIRCULATION (2004)
Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia
P Nerheim et al.
CIRCULATION (2004)
Elevated heart rate: A major risk factor for cardiovascular disease
P Palatini et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2004)
Contributions of heart rate and contractility to myocardial oxygen balance during exercise
P Colin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure
A Palazzuoli et al.
EUROPEAN JOURNAL OF HEART FAILURE (2002)
Effect of carvedilol on the morbidity of patients with severe chronic heart failure - Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study
M Packer et al.
CIRCULATION (2002)
Carvedilol decreases elevated oxidative stress in human failing myocardium
K Nakamura et al.
CIRCULATION (2002)
An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset
MJ Byrne et al.
JOURNAL OF CARDIAC FAILURE (2002)
Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period
A Benetos et al.
CIRCULATION (2002)
Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption
UE Heidland et al.
CIRCULATION (2001)
Precipitating factors and decision-making processes of short-term worsening heart failure despite Optimal treatment (from the IN-CHF registry)
C Opasich et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBISII trial
P Lechat et al.
CIRCULATION (2001)
Treatment of congestive heart failure - current status of use of digitoxin
GG Belz et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2001)
Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure
BA Groenning et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
The effects of β1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction -: A double-blind, placebo-controlled, positron-emission tomography study
RSB Beanlands et al.
CIRCULATION (2000)
分享论文
